Basis of Presentation and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Fair Value Measurement Specific to Assets or Liability

	Fair Value Measurements at Reporting Date Using (in thousands)
	Balances as of June 30, 2024		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	331,714	$	331,714	$	—	$	—
Investment in equity securities:
Equity securities	$	13,083	$	13,083	$	—	$	—

	Fair Value Measurements at Reporting Date Using (in thousands)
	Balances as of December 31, 2023		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	18,256	$	18,256	$	—	$	—
U.S. Treasuries	$	94,523	$	94,523	$	—	$	—
Investment in equity securities:
Equity securities	$	16,489	$	16,489	$	—	$	—

Summary of Disaggregated Product Revenue

The following table summarizes the Company’s net product revenue disaggregated by product (in thousands):

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
FIRDAPSE®	$	77,372	$	64,898	$	144,214	$	122,424
FYCOMPA®+		36,535		34,579		66,960		62,357
AGAMREE®*		8,746		—		9,920		—
Total product revenue, net	$	122,653	$	99,477	$	221,094	$	184,781

_________________

+FYCOMPA® net product revenue for the six months ended June 30, 2023 is for the period between January 24, 2023 (date of acquisition) and June 30, 2023.

*AGAMREE® net product revenue for the six months ended June 30, 2024 is for the period between March 13, 2024 (date of commercial launch) and June 30, 2024.

Summary of Percentage of the Company's Total Net Product Revenue

The following table illustrates the approximate percentage of the Company’s total net product revenue attributed to the Company’s largest customers for the periods presented:

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2024			2023			2024			2023
Customer A		70.2	%		65.2	%		69.7	%		66.3	%
Customer B*		—			34.8	%		—			33.7	%
Customer C		11.2	%		—			10.4	%		—
Total		81.4	%		100.0	%		80.1	%		100.0	%

*During 2023, the Company sold FYCOMPA® through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA® is being sold and distributed through a third-party logistics (3PL) organization. Customers B and C both relate to sales of FYCOMPA®.

Basic and Dilutive Weighted Average Common Shares

The following table reconciles basic and diluted weighted average common shares:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
Basic weighted average common shares    outstanding		118,180,396		106,258,790		117,493,257		105,911,936
Effect of dilutive securities		6,475,603		7,414,744		6,535,495		7,928,219
Diluted weighted average common shares    outstanding		124,655,999		113,673,534		124,028,752		113,840,155